CARGO Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update
May 14, 2024 16:05 ET
|
Cargo Therapeutics, Inc.
CARGO Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update
Health Canada Approves Saladax’s 5-Fluorouracil Chemotherapy Therapeutic Drug Monitoring (TDM) Test
May 14, 2024 10:00 ET
|
Saladax Biomedical, Inc.
Bethlehem, PA, May 14, 2024 (GLOBE NEWSWIRE) -- Saladax Biomedical, Inc. (Saladax) is pleased to announce that Health Canada has approved Saladax’s 5-Fluorouracil (My5-FU) Assay for sale in Canada...
Kymera Therapeutics to Present New Clinical Data from the Ongoing Phase 1 Trial of STAT3 Degrader KT-333 at EHA Annual Meeting
May 14, 2024 10:00 ET
|
Kymera Therapeutics, Inc.
Abstract released today highlights safety, pharmacodynamic and clinical response data collected through February 6, 2024 cut-off date Updated data to be presented at the European Hematology...
Shuttle Pharma Provides First Quarter 2024 Corporate Update
May 14, 2024 09:00 ET
|
Shuttle Pharmaceuticals Holdings, Inc.
GAITHERSBURG, Md., May 14, 2024 (GLOBE NEWSWIRE) -- Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH) (“Shuttle Pharma”), a discovery and development stage specialty pharmaceutical company...
Mural Oncology Announces First Quarter 2024 Financial Results and Provides Business Update
May 14, 2024 07:00 ET
|
Mural Oncology, Inc.
Mural Oncology reiterates cash runway projection into 4Q 2025, with sufficient capital to fund key clinical readouts.
Nouscom Appoints Leading Cancer Drug Development Expert, Neil Gallagher, MD, PhD, as Independent Advisor to its Board and Chair of its R&D Committee
May 14, 2024 03:00 ET
|
Nouscom Srl
Dr. Gallagher, current President of R&D at Syndax Pharmaceuticals and former Chief Medical Officer and Head of Development at AbbVie, brings significant experience of end-to-end development that...
Allogene Therapeutics Announces Pricing of $110 million Offering of Common Stock
May 13, 2024 16:47 ET
|
Allogene Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., May 13, 2024 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T...
Cardiff Oncology to Present at Upcoming Investor Conferences in May
May 13, 2024 16:05 ET
|
Cardiff Oncology, Inc.
SAN DIEGO, May 13, 2024 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of...
Senti Bio Announces First Patient Dosed in Phase 1 Clinical Trial of SENTI-202 for the Treatment of Relapsed or Refractory Hematologic Malignancies Including Acute Myeloid Leukemia
May 13, 2024 08:15 ET
|
Senti Biosciences, Inc.
Senti Bio today announced that patient dosing has commenced in the Phase 1 clinical trial of SENTI-202.
Compass Therapeutics Reports 2024 First Quarter Financial Results and Provides Corporate Update
May 13, 2024 08:00 ET
|
Compass Therapeutics
Received FDA Fast Track Designation for the investigation of CTX-009 in combination with paclitaxel for the treatment of patients with metastatic or locally advanced biliary tract tumors. Enrollment...